Tests nucresiran against placebo in people with transthyretin amyloidosis heart disease
Tests nucresiran against a placebo in adults with heart disease from transthyretin amyloidosis.
Plain-language title generated from the registry record
Registry title: TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Key facts
- Where
- Aarhus N, Copenhagen Oe, and Odense C, DenmarkSee the 3 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with transthyretin amyloidosis (ATTR) with heart disease, who have had heart failure. It compares nucresiran with placebo.
- Age
- 18 to 85 years
- Sex
- All sexes
- Disease stage
- ATTR amyloidosis with cardiomyopathy, hereditary or wild-type. History of heart failure with at least 1 hospital stay for it, or symptoms that need a diuretic.
- Earlier treatment
- Can be taking approved TTR stabilizers (for example tafamidis, acoramidis) and heart failure treatment. Cannot have had, or be getting, TTR-lowering therapy.
- Biomarker or test result
- NT-proBNP above 300 ng/L and below 8500 ng/L. With permanent or persistent atrial fibrillation: above 600 ng/L and below 8500 ng/L.
Main reasons for not taking part
- NYHA Class IV heart failure
- NYHA Class III heart failure together with ATTR Amyloidosis Disease Stage 3
- Polyneuropathy disability (PND) score IIIa, IIIb, or IV
- eGFR below 30 mL/min/1.73m^2 at screening
- Past or current TTR-lowering therapy
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07052903, who can take part
Where in Denmark
- Region MidtjyllandAarhus N, DenmarkTaking people
- RigshospitaletCopenhagen Oe, DenmarkTaking people
- Odense University HospitalOdense C, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT07052903EU 2024-519917-72-00
- Record updated
- 20 October 2026
- Original description
The purpose of this study is to:Read full original descriptionShow less
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
The purpose of this study is to:
* Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Inclusion: Has documented diagnosis of ATTR amyloidosis with cardiomyopathy including those with hereditary ATTR (hATTR) or wild-type ATTR (wATTR) amyloidosis; Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF or signs and symptoms that require treatment with a diuretic; Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) >300 ng/L and <8500 ng/L; In patients with permanent or persistent atrial fibrillation, screening NT-proBNP >600 ng/L and <8500 ng/L; Patients may be receiving approved TTR stabilizers for ATTR amyloidosis (eg, tafamidis, acoramidis) and may be receiving background therapy for HF at the discretion of the Investigator.
Exclusion: Has received prior or currently receiving TTR-lowering therapy; Has New York Heart Association (NYHA) Class IV HF; or NYHA Class III heart failure AND ATTR Amyloidosis Disease Stage 3; Has an estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73m\^2 at screening; Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV.